CompletedPhase 4NCT02348177
Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB
Studying Primary genito-urinary tuberculosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Drugs for Neglected Diseases
- Principal Investigator
- Mark Cotton, ProfessorUniversity of Stellenbosch
- Intervention
- lopinavir with ritonavir in 1:1 ratio(drug)
- Enrollment
- 96 enrolled
- Eligibility
- All sexes
- Timeline
- 2013 – 2016
Study locations (5)
- The Children's Infectious Disease Clinical Research Unit; University of Stellenbosch, Cape Town, Western Cape, South Africa
- Enhancing Care Foundation; Wendworth Hospital, Durban, South Africa
- Perinatal HIV Research Unit, Johannesburg, South Africa
- Shandukani Research WRHI, Johannesburg, South Africa
- Empilweni Services and Research Unit, Johannesburg, South Africa
Collaborators
University of Cape Town · Medecins Sans Frontieres, Netherlands · French Development Agency · UBS Optimus Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02348177 on ClinicalTrials.govOther trials for Primary genito-urinary tuberculosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05917210Peer-led Implementation of TB-HIV Education and Adherence Counseling in UgandaYale University
- RECRUITINGNCT07312266Questioning the Epidemiology of Asymptomatic TBBarcelona Institute for Global Health
- RECRUITINGNANCT05842161South Africa Smoking Cessation and Engagement in HIV/TB Care CareMassachusetts General Hospital
- RECRUITINGPHASE3NCT05575518A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary TuberculosisStellah Mpagama
- ACTIVE NOT RECRUITINGPHASE4NCT05118490Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis PatientsThe Aurum Institute NPC
- RECRUITINGNANCT05342064Closing -TB GAPs - for People Living With HIV: TB Guidance for Adaptable Patient-Centered ServiceBaylor College of Medicine